Automate Your Wheel Strategy on IMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including IMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMRN
- Rev/Share 0.0342
- Book/Share 0.0453
- PB 1.4357
- Debt/Equity 0.0131
- CurrentRatio 6.8
- ROIC -0.6828
- MktCap 14897358.5429
- FreeCF/Share -0.043
- PFCF -1.5189
- PE -1.5171
- Debt/Assets 0.0111
- DivYield 0
- ROE -0.849
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Immuron - FY25 global sales exceed projection, up 49% on prior year
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement …
Read More
About Immuron Limited (IMRN)
- IPO Date 2017-06-09
- Website https://www.immuron.com.au
- Industry Biotechnology
- CEO Steven George Lydeamore CPA,
- Employees 7